Insider Trading Alert - ROP, GEVO And ACOR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 15, 2015, 111 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,266.50 to $281,749,912.50.

Highlighted Stocks Traded by Insiders:

Roper Technologies (ROP) - FREE Research Report

Wright Christopher, who is Director at Roper Technologies, sold 8,000 shares at $175.32 on May 15, 2015. Following this transaction, the Director owned 69,784 shares meaning that the stake was reduced by 10.28% with the 8,000-share transaction.

The shares most recently traded at $175.60, up $0.28, or 0.16% since the insider transaction. Historical insider transactions for Roper Technologies go as follows:

  • 4-Week # shares sold: 37,314
  • 12-Week # shares sold: 70,114
  • 24-Week # shares sold: 73,614

The average volume for Roper Technologies has been 412,800 shares per day over the past 30 days. Roper Technologies has a market cap of $17.7 billion and is part of the industrial goods sector and industrial industry. Shares are up 12.79% year-to-date as of the close of trading on Friday.

Roper Technologies, Inc., a diversified technology company, designs and develops software (both license and software-as-a-service), and engineered products and solutions for healthcare, transportation, food, energy, water, education, and academic research markets worldwide. The stock currently has a dividend yield of 0.57%. The company has a P/E ratio of 27.2. Currently, there are 5 analysts who rate Roper Technologies a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ROP - FREE

TheStreet Quant Ratings rates Roper Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Roper Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gevo (GEVO) - FREE Research Report

Ryan Christopher Michael, who is President and COO at Gevo, sold 121 shares at $5.51 on May 15, 2015. Following this transaction, the President and COO owned 21,352 shares meaning that the stake was reduced by 0.56% with the 121-share transaction.

The shares most recently traded at $2.78, down $2.73, or 98.2% since the insider transaction. Historical insider transactions for Gevo go as follows:

  • 4-Week # shares bought: 181,484
  • 4-Week # shares sold: 1,897
  • 12-Week # shares bought: 181,484
  • 12-Week # shares sold: 30,537
  • 24-Week # shares bought: 181,484
  • 24-Week # shares sold: 92,590

The average volume for Gevo has been 326,100 shares per day over the past 30 days. Gevo has a market cap of $23.6 million and is part of the basic materials sector and chemicals industry. Shares are down 58.12% year-to-date as of the close of trading on Tuesday.

Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The company operates in two segments, Gevo, Inc.; and Gevo Development/Agri-Energy.

Exclusive Offer: Get the latest Stock Analysis on GEVO - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Acorda Therapeutics (ACOR) - FREE Research Report

Hindman Andrew A., who is Chief Business Dev. Officer at Acorda Therapeutics, sold 4,779 shares at $29.82 on May 15, 2015. Following this transaction, the Chief Business Dev. Officer owned 54,972 shares meaning that the stake was reduced by 8% with the 4,779-share transaction.

The shares most recently traded at $30.16, up $0.34, or 1.14% since the insider transaction. Historical insider transactions for Acorda Therapeutics go as follows:

  • 4-Week # shares sold: 21,626
  • 12-Week # shares sold: 21,626
  • 24-Week # shares sold: 21,626

The average volume for Acorda Therapeutics has been 672,500 shares per day over the past 30 days. Acorda Therapeutics has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are down 27.11% year-to-date as of the close of trading on Friday.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company has a P/E ratio of 87.9. Currently, there are 2 analysts who rate Acorda Therapeutics a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACOR - FREE

TheStreet Quant Ratings rates Acorda Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Acorda Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks